Profile data is unavailable for this security.
About the company
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
- Revenue in USD (TTM)610.81m
- Net income in USD-41.97m
- Incorporated2000
- Employees1.97k
- LocationHUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
- Phone+852 21281188
- Fax+852 21281778
- Websitehttps://www.hutch-med.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 2.06bn | 246.00 | 17.08 | 3.45 | 14.01 | 3.02 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 2.22bn | 58.00 | 54.50 | 2.83 | 28.66 | 16.60 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.34bn | 1.76k | 15.39 | 3.32 | 10.64 | 3.28 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Vericel Corp | 214.52m | 789.00k | 2.65bn | 314.00 | 2,855.63 | 10.86 | 445.88 | 12.34 | 0.0189 | 0.0189 | 4.46 | 4.97 | 0.624 | 4.41 | 4.97 | 683,184.70 | 0.2295 | -3.07 | 0.2595 | -3.50 | 70.42 | 67.87 | 0.3678 | -4.49 | 4.16 | -- | 0.0008 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Twist Bioscience Corp | 295.21m | -220.31m | 2.66bn | 919.00 | -- | 5.41 | -- | 9.01 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.70bn | 7.70k | -- | -- | 29.36 | 1.04 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.85bn | 167.00 | 20.42 | 4.32 | 15.83 | 6.20 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| HUTCHMED (China) Ltd (ADR) | 610.81m | -41.97m | 3.11bn | 1.97k | -- | 4.23 | -- | 5.10 | -0.2497 | -0.2497 | 3.54 | 4.25 | 0.4775 | 7.10 | 4.15 | 307,246.50 | -3.30 | -- | -4.65 | -- | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.41bn | 988.00 | -- | -- | -- | 3.78 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Perrigo Company PLC | 4.39bn | -146.90m | 3.60bn | 9.14k | -- | 0.788 | 19.48 | 0.8188 | -1.07 | -1.17 | 32.07 | 33.45 | 0.40 | 2.46 | 5.58 | 480,525.20 | -1.34 | -0.1148 | -1.51 | -0.1315 | 36.07 | 35.28 | -3.34 | -0.2985 | 1.77 | 1.26 | 0.51 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Apellis Pharmaceuticals Inc | 715.22m | -250.10m | 3.73bn | 702.00 | -- | 15.43 | -- | 5.21 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.95m | 3.98bn | 570.00 | 19.58 | 2.29 | 16.77 | 3.59 | 4.11 | 4.11 | 22.14 | 35.03 | 0.334 | 3.13 | 6.90 | 1,948,525.00 | 6.19 | 3.69 | 6.42 | 3.84 | 55.21 | 56.79 | 18.54 | 12.19 | 2.10 | 5.68 | 0.3779 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| Organon & Co | 6.41bn | 1.30bn | 4.13bn | 10.00k | 3.18 | 8.38 | 2.65 | 0.6446 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
Data as of Nov 11 2024. Currency figures normalised to HUTCHMED (China) Ltd's reporting currency: US Dollar USD
4.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management (Hong Kong) Ltd.as of 30 Jun 2024 | 1.63m | 0.94% |
| Allianz Global Investors Asia Pacific Ltd.as of 30 Jun 2024 | 1.44m | 0.82% |
| Schroder Investment Management (Singapore) Ltd.as of 30 Jun 2024 | 1.39m | 0.80% |
| Bellevue Asset Management AGas of 30 Jun 2024 | 1.15m | 0.66% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 389.12k | 0.22% |
| Millennium Management LLCas of 30 Jun 2024 | 357.63k | 0.21% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 346.45k | 0.20% |
| AIA Investment Management Pte Ltd.as of 30 Sep 2024 | 315.44k | 0.18% |
| M&G Investment Management Ltd.as of 30 Sep 2024 | 267.23k | 0.15% |
| BNP Paribas Financial Marketsas of 30 Jun 2024 | 191.15k | 0.11% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
